Making the case for the development of a vaccination against hepatitis E virus

Samir Haffar, Fateh Bazerbachi, John R. Lake

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Hepatitis E virus (HEV) infection is a global problem that affects 20 million individuals, and cause acute hepatitis in 3.5 million, with approximately 70 000 deaths worldwide per year. While the acute disease is generally self-limited, however, it may progress to fatal fulminant liver failure in certain individuals. Contaminated water supplies disseminate this virus through the faecal-oral route, and swine is thought to be its zoonotic reservoir. Attempts have been made to develop effective HEV vaccines, and two candidates have undergone successful clinical trials. In this review, we discuss HEV epidemiology, genotypes, microbiological structure, as well as the most recent advances in vaccination developments.

Original languageEnglish (US)
Pages (from-to)311-316
Number of pages6
JournalLiver International
Issue number2
StatePublished - Feb 1 2015

Bibliographical note

Publisher Copyright:
© 2014 John Wiley & Sons A/S.


  • HEV vaccine
  • Hepatitis E virus (HEV)
  • Primary prevention
  • Vaccination
  • Viral hepatitis


Dive into the research topics of 'Making the case for the development of a vaccination against hepatitis E virus'. Together they form a unique fingerprint.

Cite this